Opioid use disorder and the COVID 19 pandemic: A call to sustain regulatory easements and further expand access to treatment

被引：87

作者：

Green, Traci C. ^{[1
,2
]}

Bratberg, Jeffrey ^{[3
]}

Finnell, Deborah S. ^{[4
]}

机构：

[1] Brandeis Univ, Heller Sch Social Policy & Management, Inst Behav Hlth, Opioid Policy Res Collaborat, Waltham, MA USA

[2] Brown Univ, Rhode Isl Hosp, Warren Alpert Sch Med, Dept Emergency Med & Epidemiol, Providence, RI 02903 USA

[3] Univ Rhode Isl, Coll Pharm, Kingston, RI 02881 USA

[4] Johns Hopkins Sch Nursing, Baltimore, MD 21205 USA

来源：

SUBSTANCE ABUSE | 2020年 / 41卷 / 02期

关键词：

Pandemic; opioid use disorder; pharmacists; buprenorphine; methadone; regulations; policy; METHADONE; LEGAL;

D O I：

10.1080/08897077.2020.1752351

中图分类号：

R194 [卫生标准、卫生检查、医药管理];

学科分类号：

摘要：

We highlight the critical roles that pharmacists have related to sustaining and advancing the changes being made in the face of the current COVID-19 pandemic to ensure that patients have more seamless and less complex access to treatment. Discussed herein is how the current COVID-19 pandemic is impacting persons with substance use disorders, barriers that persist, and the opportunities that arise as regulations around treatments for this population are eased.

引用

页码：147 / 149

页数：3

共 21 条

[1]

American Pharmacists Association, 2020, Increasing access to and advocacy for medications for opioid use disorder (MOUD)

[2] In Rural Areas, Buprenorphine Waiver Adoption Since 2017 Driven By Nurse Practitioners And Physician Assistants [J].

Barnett, Michael L. ;

Lee, Dennis ;

Frank, Richard G. .

HEALTH AFFAIRS, 2019, 38 (12) :2048-2056

[3] Methadone Matters: What the United States Can Learn from the Global Effort to Treat Opioid Addiction [J].

Calcaterra, S. L. ;

Bach, P. ;

Chadi, A. ;

Chadi, N. ;

Kimmel, S. D. ;

Morford, K. L. ;

Roy, P. ;

Samet, J. H. .

JOURNAL OF GENERAL INTERNAL MEDICINE, 2019, 34 (06) :1039-1042

[4]

Committee on the Examination of the Integration of Opioid and Infectious Disease Prevention Efforts in Select Programs Board on Population Health and Public Health Practice Health and Medicine Division National Academies of Sciences Engineering and Medicine., 2020, OPP IMPR OP US DIS I

[5] Promising roles for pharmacists in addressing the US opioid crisis [J].

Compton, Wilson M. ;

Jones, Christopher M. ;

Stein, Jack B. ;

Wargo, Eric M. .

RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2019, 15 (08) :910-916

[6] Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States [J].

Davis, Corey S. ;

Carr, Derek H. .

INTERNATIONAL JOURNAL OF DRUG POLICY, 2019, 73 :42-48

[7]

Elflein J, 2018, NUMBER PHARM US 2001

[8] Buprenorphine Deregulation and Mainstreaming Treatment for Opioid Use Disorder X the X Waiver [J].

Fiscella, Kevin ;

Wakeman, Sarah E. ;

Beletsky, Leo .

JAMA PSYCHIATRY, 2019, 76 (03) :229-230

[9] No end to the crisis without an end to the waiver [J].

Frank, Joseph W. ;

Wakeman, Sarah E. ;

Gordon, Adam J. .

SUBSTANCE ABUSE, 2018, 39 (03) :263-265

[10] Pharmacy on-site overdose protocols and prevention of overdose [J].

Green, Traci C. ;

Soipe, Ayorinde ;

Baloy, Brianna ;

Burstein, Dina ;

Xuan, Ziming ;

Tapper, Abigail ;

Walley, Alexander Y. ;

Case, Patricia ;

Bratberg, Jeffrey ;

Baird, Janette .

SUBSTANCE ABUSE, 2022, 43 (01) :64-68

← 1 2 3 →